EGFR and central nervous system cancer: We treated mice bearing a BRAFV600E heterozygous mutant pediatric glioma, BT40, with BRAFV600E specific inhibitor PLX4720 (10 mg/kg), EGFR inhibitor HKI-272 (40 mg/kg), or a combination of PLX4720 (10 mg/kg) and HKI-272 (40 mg/kg) for 14 days.